Perrigo Appoints New EVP of Global Operations

An update from Perrigo Company ( (PRGO) ) is now available.

On June 2, 2025, Perrigo Company announced the planned retirement of Ronald Janish, Executive Vice President of Global Operations and Supply Chain, effective June 23, 2025. Mr. Janish will continue in an advisory role until September 30, 2025, and will receive a severance package upon his departure. On June 4, 2025, Perrigo appointed Matt Winterman as the new Executive Vice President of Global Operations and Supply Chain, effective June 23, 2025. Mr. Winterman, with over 20 years of experience in global supply chain and strategy leadership, previously held senior positions at AstraZeneca, Roche Holding AG, and GSK plc. His appointment is expected to advance Perrigo’s manufacturing and supply chain capabilities, supporting the company’s long-term consumer self-care strategy.

The most recent analyst rating on (PRGO) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on Perrigo Company stock, see the PRGO Stock Forecast page.

Spark’s Take on PRGO Stock

According to Spark, TipRanks’ AI Analyst, PRGO is a Neutral.

Perrigo’s overall stock score reflects significant financial challenges, with declining sales and persistent losses weighing heavily. However, the company is making strategic efforts to improve profitability and operational efficiencies, as evidenced by recent earnings call highlights. Technical analysis suggests neutral stock movement, while valuation metrics call for caution due to negative earnings. The dividend yield offers some investor appeal, but risks remain due to macroeconomic uncertainties and cost pressures.

To see Spark’s full report on PRGO stock, click here.

More about Perrigo Company

Perrigo Company plc is a leading pure-play self-care company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. As a pioneer in the over-the-counter (OTC) self-care market, Perrigo offers trusted self-care solutions that can be used without the need for a prescription, ensuring accessibility and choice for consumers across molecules, dosage forms, and value tiers.

Average Trading Volume: 1,522,171

Technical Sentiment Signal: Sell

Current Market Cap: $3.67B

For an in-depth examination of PRGO stock, go to TipRanks’ Stock Analysis page.